Gilead saves US$10b in taxes as pricey hep C drug takes off
This boosts its already huge profits, letting firm stash even more billions in tax havens abroad, says advocacy group
New York
GILEAD Sciences Inc's profit margin has soared and its tax rate has plummeted since the drugmaker introduced its controversial US$1,000-a- day medication for hepatitis C, according to a report by an advocacy group that accuses the company of using accounting gimmicks to stash billions in earnings in tax havens offshore.
By moving some of its intellectual property to Ireland, Gilead was able to employ a common strategy that cut its US tax bill by US$10 billion since 2013, according to Americans for Tax Fairness (ATF), a left-leaning think-tank.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Shareholders raise questions over dividend payout, directors’ salaries at Best World AGM ahead of proposed privatisation
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue